As previously reported, Raymond James analyst Dane Leone downgraded Galapagos (GLPG) to Market Perform from Strong Buy after the company and Gilead (GILD) announced a major expansion of the current collaboration agreement and partnership between the two companies. The analyst believes Galapagos' stock has now fully realized his price target by achieving his core investment thesis. He retains a positive viewpoint of Galapagos within the context of the relationship expansion with Gilead, but will be watching for how key 2020 value drivers develop over the course of the second half of 2019.

Cantor Fitzgerald lowered the firm's price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The "usual seasonal headwinds that typically make this one of the weaker quarters for the industry," the analyst added in the preview note.